MINNEAPOLIS, Oct. 9 /PRNewswire/ -- CELLEX BIOSCIENCES, Inc.
(Nasdaq: CLXX), today announced that its common stock and warrants have been
delisted from The Nasdaq SmallCap Market.
    CELLEX failed to meet the Nasdaq net tangible assets requirement as of
February 28, 1998, the date Nasdaq's new listing requirements became
effective. The company requested a temporary exception to those requirements,
subject to meeting certain conditions. The company was unable to obtain such
an exemption, and on October 7, Nasdaq notified the company that its
securities were being deleted from The Nasdaq SmallCap Market because of
failure to meet the bid price, net tangible assets and public float
requirements.
    CELLEX BIOSCIENCES, Inc. is dedicated to providing cell processing
products and services to meet the needs of human health care and biotechnology
markets worldwide with stirred tank cell culturing systems, freeze dryers and
perfusion technology.
    CELLEX BIOSCIENCES is headquartered in Minneapolis, Minn., with
subsidiaries in England, France, Switzerland and the United States.

Link to this page: